293 related articles for article (PubMed ID: 36207299)
1. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
[TBL] [Abstract][Full Text] [Related]
2. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
Wang Y; Liu M; Shen Y; Ma Y; Li X; Zhang Y; Liu M; Yang XL; Chen J; Yan R; Luan D; Wang Y; Chen Y; Wang Q; Lin H; Li Y; Wu K; Zhu T; Zhao J; Lu H; Wen Y; Jiang S; Wu F; Zhou Q; Shi ZL; Huang J
Cell Discov; 2022 Apr; 8(1):36. PubMed ID: 35443747
[TBL] [Abstract][Full Text] [Related]
3. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
[TBL] [Abstract][Full Text] [Related]
4. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
5. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
6. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
[TBL] [Abstract][Full Text] [Related]
7. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
8. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
9. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages.
Ren P; Hu Y; Peng L; Yang L; Suzuki K; Fang Z; Bai M; Zhou L; Feng Y; Zou Y; Xiong Y; Chen S
bioRxiv; 2023 Mar; ():. PubMed ID: 35982661
[TBL] [Abstract][Full Text] [Related]
10. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
[TBL] [Abstract][Full Text] [Related]
11. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
[TBL] [Abstract][Full Text] [Related]
12. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
13. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration.
Ma H; Zhang X; Zeng W; Zhou J; Chi X; Chen S; Zheng P; Wang M; Wu Y; Zhao D; Gong F; Lin H; Sun H; Yu C; Shi Z; Hu X; Zhang H; Jin T; Chiu S
Cell Discov; 2022 Dec; 8(1):132. PubMed ID: 36494344
[TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
[TBL] [Abstract][Full Text] [Related]
15. A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022.
Yu K; Liu B; Yu H; Sun C; Wang X; Li G; Dong M; Wang Y; Zhang J; Xu N; Liu W
Front Cell Infect Microbiol; 2023; 13():1155293. PubMed ID: 37207187
[TBL] [Abstract][Full Text] [Related]
16. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.
Xu Y; Wu C; Cao X; Gu C; Liu H; Jiang M; Wang X; Yuan Q; Wu K; Liu J; Wang D; He X; Wang X; Deng SJ; Xu HE; Yin W
Cell Res; 2022 Jul; 32(7):609-620. PubMed ID: 35641567
[TBL] [Abstract][Full Text] [Related]
17. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799
[TBL] [Abstract][Full Text] [Related]
18. A novel consensus-based computational pipeline for screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including Omicron variant.
Kumar N; Kaushik R; Zhang KYJ; Uversky VN; Sahu U; Sood R; Bhatia S
Proteins; 2023 Jun; 91(6):798-806. PubMed ID: 36629264
[TBL] [Abstract][Full Text] [Related]
19. Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape.
Zhao Z; Zhou J; Tian M; Huang M; Liu S; Xie Y; Han P; Bai C; Han P; Zheng A; Fu L; Gao Y; Peng Q; Li Y; Chai Y; Zhang Z; Zhao X; Song H; Qi J; Wang Q; Wang P; Gao GF
Nat Commun; 2022 Aug; 13(1):4958. PubMed ID: 36002453
[TBL] [Abstract][Full Text] [Related]
20. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
